NEW YORK, September 11, 2017 /PRNewswire/ --
If you want a Stock Review on SHPG, AERI, HRTX, or UTHR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has investors' focus onto the Healthcare sector, which is made up of companies that specialize in products and services related to health and medical care. Examples of these companies include, but are not limited to, biotechnology companies, health insurance providers, pharmaceutical companies, and companies that manage clinics and hospitals. Equities in this morning's lineup are: Shire PLC (NASDAQ: SHPG), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Heron Therapeutics Inc. (NASDAQ: HRTX), and United Therapeutics Corp. (NASDAQ: UTHR). Register now and get full and free access to these DailyStockTracker.com research reports at:
http://dailystocktracker.com/register/
Shire
Dublin, Ireland headquartered Shire PLC's shares recorded a trading volume of 1.28 million shares last Friday. The stock finished the trading session 1.44% higher at $160.08. The Company's shares have gained 4.04% in the last one month. The stock is trading above its 50-day moving average by 1.57%. Furthermore, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have a Relative Strength Index (RSI) of 66.33.
On August 15th, 2017, Shire announced that the Marketing Authorization Application for lifitegrast, which was submitted on August 07th, 2017, has been validated by the UK as the Reference Member State involved in the Decentralized Procedure. If approved, lifitegrast would be the first and only treatment in a new class of drugs (LFA-1 antagonist) to address the signs and symptoms of dry eye disease in adults in Europe.
On August 17th, 2017, research firm Evercore ISI initiated an 'Outperform' rating on the Company's stock, with a target price of $196 per share. Access our complete research report on SHPG for free at:
http://dailystocktracker.com/registration/?symbol=SHPG
Aerie Pharmaceuticals
On Friday, Irvine, California-based Aerie Pharmaceuticals Inc.'s stock ended the session 0.77% lower at $58.25. A total volume of 415,389 shares was traded. The Company's shares have gained 12.24% in the last one month, 13.66% over the previous three months, and 53.90% on an YTD basis. The stock is trading 6.80% above its 50-day moving average and 24.61% above its 200-day moving average. Moreover, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have an RSI of 61.79.
On September 06th, 2017, Aerie Pharma announced that its management will present at the Rodman & Renshaw 19th Annual Global Investment Conference (sponsored by H.C. Wainwright & Co., LLC) on September 12th, 2017, at 12:30 p.m. ET in New York. Management will also present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th, 2017, at 9:10 a.m. ET in New York. The complimentary research report on AERI can be downloaded at:
http://dailystocktracker.com/registration/?symbol=AERI
Heron Therapeutics
Redwood City, California headquartered Heron Therapeutics Inc.'s stock ended the day 3.61% lower at $16.00 with a total trading volume of 673,931 shares. The Company's shares have gained 4.58% in the last month, 18.52% over the previous three months, and 22.14% on an YTD basis. The stock is trading 2.09% and 9.57% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 52.00. Register for free on DailyStockTracker.com and get access to the latest report on HRTX at:
http://dailystocktracker.com/registration/?symbol=HRTX
United Therapeutics
Shares in Silver Spring, Maryland headquartered United Therapeutics Corp. recorded a trading volume of 2.28 million shares, which was above their three months average volume of 572,400 shares. The stock ended Friday's session 9.51% lower at $120.82. The Company's shares are trading below their 50-day moving average by 7.50%. Furthermore, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 33.99.
On September 07th, 2017, United Therapeutics announced that the independent data monitoring committee (DMC) for the FREEDOM-EV study of Orenitram (treprostinil) extended-release tablets had completed a pre-specified interim safety and efficacy analysis. The DMC did not identify any new safety concerns associated with Orenitram therapy, and recommended that the trial be continued as planned without modification. Download your free research report on UTHR at:
http://dailystocktracker.com/registration/?symbol=UTHR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
Advertisement
If you want a Stock Review on SHPG, AERI, HRTX, or UTHR then come over to http://dailystocktracker.com/register/ and sign up for your free customized report today. DailyStockTracker.com has investors' focus onto the Healthcare sector, which is made up of companies that specialize in products and services related to health and medical care. Examples of these companies include, but are not limited to, biotechnology companies, health insurance providers, pharmaceutical companies, and companies that manage clinics and hospitals. Equities in this morning's lineup are: Shire PLC (NASDAQ: SHPG), Aerie Pharmaceuticals Inc. (NASDAQ: AERI), Heron Therapeutics Inc. (NASDAQ: HRTX), and United Therapeutics Corp. (NASDAQ: UTHR). Register now and get full and free access to these DailyStockTracker.com research reports at:
Advertisement
http://dailystocktracker.com/register/
Shire
Dublin, Ireland headquartered Shire PLC's shares recorded a trading volume of 1.28 million shares last Friday. The stock finished the trading session 1.44% higher at $160.08. The Company's shares have gained 4.04% in the last one month. The stock is trading above its 50-day moving average by 1.57%. Furthermore, shares of Shire, which together with its subsidiaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products, have a Relative Strength Index (RSI) of 66.33.
On August 15th, 2017, Shire announced that the Marketing Authorization Application for lifitegrast, which was submitted on August 07th, 2017, has been validated by the UK as the Reference Member State involved in the Decentralized Procedure. If approved, lifitegrast would be the first and only treatment in a new class of drugs (LFA-1 antagonist) to address the signs and symptoms of dry eye disease in adults in Europe.
On August 17th, 2017, research firm Evercore ISI initiated an 'Outperform' rating on the Company's stock, with a target price of $196 per share. Access our complete research report on SHPG for free at:
http://dailystocktracker.com/registration/?symbol=SHPG
Aerie Pharmaceuticals
On Friday, Irvine, California-based Aerie Pharmaceuticals Inc.'s stock ended the session 0.77% lower at $58.25. A total volume of 415,389 shares was traded. The Company's shares have gained 12.24% in the last one month, 13.66% over the previous three months, and 53.90% on an YTD basis. The stock is trading 6.80% above its 50-day moving average and 24.61% above its 200-day moving average. Moreover, shares of Aerie Pharma, which focuses on the discovery, development, and commercialization of first-in-class therapies for the treatment of glaucoma and other eye diseases, have an RSI of 61.79.
On September 06th, 2017, Aerie Pharma announced that its management will present at the Rodman & Renshaw 19th Annual Global Investment Conference (sponsored by H.C. Wainwright & Co., LLC) on September 12th, 2017, at 12:30 p.m. ET in New York. Management will also present at the Cantor Fitzgerald 2017 Global Healthcare Conference on September 27th, 2017, at 9:10 a.m. ET in New York. The complimentary research report on AERI can be downloaded at:
http://dailystocktracker.com/registration/?symbol=AERI
Heron Therapeutics
Redwood City, California headquartered Heron Therapeutics Inc.'s stock ended the day 3.61% lower at $16.00 with a total trading volume of 673,931 shares. The Company's shares have gained 4.58% in the last month, 18.52% over the previous three months, and 22.14% on an YTD basis. The stock is trading 2.09% and 9.57% above its 50-day and 200-day moving averages, respectively. Additionally, shares of Heron Therapeutics, which develops products to address unmet medical needs using its proprietary Biochronomer polymer-based drug delivery platform in the US, have an RSI of 52.00. Register for free on DailyStockTracker.com and get access to the latest report on HRTX at:
http://dailystocktracker.com/registration/?symbol=HRTX
United Therapeutics
Shares in Silver Spring, Maryland headquartered United Therapeutics Corp. recorded a trading volume of 2.28 million shares, which was above their three months average volume of 572,400 shares. The stock ended Friday's session 9.51% lower at $120.82. The Company's shares are trading below their 50-day moving average by 7.50%. Furthermore, shares of United Therapeutics, which develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide, have an RSI of 33.99.
On September 07th, 2017, United Therapeutics announced that the independent data monitoring committee (DMC) for the FREEDOM-EV study of Orenitram (treprostinil) extended-release tablets had completed a pre-specified interim safety and efficacy analysis. The DMC did not identify any new safety concerns associated with Orenitram therapy, and recommended that the trial be continued as planned without modification. Download your free research report on UTHR at:
http://dailystocktracker.com/registration/?symbol=UTHR
Daily Stock Tracker:
Daily Stock Tracker (DST) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. DST has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.
DST has not been compensated; directly or indirectly; for producing or publishing this document.
PRESS RELEASE PROCEDURES:
The non-sponsored content contained herein has been prepared by a writer (the "Author") and is fact checked and reviewed by a third party research service company (the "Reviewer") represented by a credentialed financial analyst [for further information on analyst credentials, please email [email protected]. Rohit Tuli, a CFA® charterholder (the "Sponsor"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by DST. DST is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.
NO WARRANTY
DST, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. DST, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, DST, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.
NOT AN OFFERING
This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither DST nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit
http://dailystocktracker.com/disclaimer/
CONTACT For any questions, inquiries, or comments reach out to us directly. If you're a company we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at: Email: [email protected] Phone number: (207)331-3313 Office Address: 377 Rivonia Boulevard, Rivonia, South Africa
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE dailystocktracker.com
